HIVEP3 and osteogenesis imperfecta: In summary, this project has identified new cellular features of OI in the SSC and vascular compartments of bone and identified preclinical evidence supporting a new therapeutic approach centering on inhibition of the SHN3 pathway with an AAV delivered payload.